株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の嚢胞性線維症市場

Cystic Fibrosis

発行 Global Industry Analysts, Inc. 商品コード 478081
出版日 ページ情報 英文 252 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.67円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
世界の嚢胞性線維症市場 Cystic Fibrosis
出版日: 2018年01月01日 ページ情報: 英文 252 Pages
概要

当レポートでは、世界の嚢胞性線維症市場について調査し、疾患の概要と市場の今後の予測、地域別動向、および市場に参入する企業のプロファイルをまとめています。

第1章 イントロダクション、調査方法、製品定義

第2章 エグゼクティブサマリー

  • 市場概要
    • 嚢胞性線維症:概要
    • 罹患率
    • 治療方法
    • 競合シナリオ
  • 嚢胞性線維症分野における研究
    • 研究開発分野
    • 遺伝子治療
    • 研究結果と革新
    • 診断と個別化治療のための診断ガイドライン
    • パイプライン薬剤
    • 開発段階別パイプライン薬剤
  • 疾患概要
    • 嚢胞性線維症
    • 遺伝子変異
    • 遺伝的リスク
    • 病態生理学
    • 症状
    • 合併症
    • 診断方法
  • 嚢胞性線維症治療:概要
    • 既存の治療法
    • 一般的薬剤
    • 嚢胞性線維症管理のための薬剤分析
    • 肺への感染のための抗生物質治療
    • 粘液溶解薬
    • 膵酵素補充療法
    • 調整剤
    • 気管支拡張剤
    • 追加的治療
    • 外科およびその他の技術
  • 臨床試験
  • 製品上市/承認
  • 近年の業界活動
  • 臨床段階別参入企業
  • 世界の主要参入企業
    • AbbVie Inc.
    • Galapagos NV
    • Genentech, Inc.
    • Gilead Sciences, Inc.
    • Novartis AG
    • Vertex Pharmaceuticals
  • 世界市場見通し

第3章 市場

  • 米国
  • カナダ
  • 欧州
  • その他の諸国

第4章 競合環境

目次
Product Code: MCP-6233

This report analyzes the worldwide markets for Cystic Fibrosis in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2022. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 56 companies including many key and niche players such as -

Advanced Inhalation Therapies (AIT) Ltd.
AbbVie Inc.
Galapagos NV
Genentech, Inc.
Gilead Sciences, Inc.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Cystic Fibrosis - A Prelude
  • CF Disease Prevalence: A Brief Note
    • Table 1: Prevalence of Cystic Fibrosis across Select Countries
  • Treatment Modalities for Cystic Fibrosis
  • CFTR Modulators: Key Drug Category
  • Competitive Scenario
    • Table 2: Leading CF Drugs on the Market (2016): Percentage Share Breakdown by Sales (includes corresponding Graph/Chart)
  • Vertex: At the Forefront of Cystic Fibrosis Therapeutics

2. RESEARCH IN CYSTIC FIBROSIS SPACE

  • Areas of Research & Development
  • Gene Therapy - A Step Towards Cure
  • Research Findings & Innovations
  • Updated CF Diagnosis Guidelines to Aid in Diagnosis and Personalized Treatment
  • Pipeline Drugs - An Overview
  • Select Pipeline Drugs for Cystic Fibrosis Treatment by Development Stage, 2016
  • Description of Select Pipeline Drugs
  • Ataluren
  • VX-661 + Ivacaftor
  • Riociguat
  • QBW251
  • CTP-656
  • Cavosonstat (N91115)
  • VX-440
  • QR-010
  • pGM169/GL67A
  • Acebilustat
  • Resunab
  • Inhaled Mannitol
  • VX-371
  • Inhaled Levoflaxacin (Quinsair)
  • AeroVanc (Vancomycin Inhalation Powder)

3. DISEASE OVERVIEW

  • Cystic Fibrosis - A Hereditary Disease
  • Mutation in CFTR Gene - A Major Cause of CF
  • ?F508 - The Most Common Mutation that Affects CFTR Protein
    • Table 3: Most Common Mutations and Worldwide Frequency (includes corresponding Graph/Chart)
  • Hereditary Risk of the Disease
  • Pathophysiology of the Disease
  • Symptoms of Cystic Fibrosis
  • Common Symptoms in Early Childhood
  • Common Symptoms in Grownups or Adults:
  • Complications Associated with Cystic Fibrosis
  • Sinus and Lung Illness
  • Pancreatic, Gastrointestinal, and Liver Disease
  • Endocrine Disorders
  • Infertility
  • Diagnosis of Cystic Fibrosis
  • Newborn Test
  • Sweat Test
  • The IRT Test
  • Carrier Test
  • Antenatal Test
  • Other Common Tests
  • Prenatal Diagnosis of Cystic Fibrosis
  • Tests to Diagnose CF-Related Complications
  • Cystic Fibrosis in Children

4. CYSTIC FIBROSIS TREATMENT: AN OVERVIEW

5. CLINICAL STUDIES

  • Vertex Pharmaceuticals Announces Positive Phase 3 Study Results of ORKAMBI
  • ProQR Therapeutics Announces Positive Proof-of-Concept Study for QR-010
  • Concert Pharmaceuticals Presents Positive Food Effect Results for CTP-656
  • Vertex Pharmaceuticals Initiates Phase 2 Studies for VX-440 & VX-152
  • Vertex Pharmaceuticals Provides Update on Phase 3 Study of VX-661 with ivacaftor
  • Protalix BioTherapeutics Announces Start of Phase II Trial of AIR DNase(tm) (PRX-110)
  • Nivalis Therapeutics Announces Completion of Enrollment for Phase 2 Study of N91115
  • Alaxia SAS Announces Agreement and Grant from CFFT for ALX-009 Studies
  • Polyphor Completes Successful Phase I Study of Inhaled POL6014
  • AlgiPharma Receives Grant from CFFT for Phase 2 Trials of OligoG
  • Health Canada Grants Clearance to ProMetic for its PBI-4050
  • Cystic Fibrosis Canada Finances Laurent Pharmaceuticals' LAU-7b Phase 2 Trial
  • Galapagos NV Begins Phase 2 Study of GLPG1837
  • Pharmaxis Announces Positive Phase II Trial Results of Bronchitol(r)
  • PTC Therapeutics Completes Enrollment for second Phase 3 clinical trial of Translarna(tm)
  • Anthera Pharmaceuticals Begins Phase 3 Study of Oral Liprotamase
  • Parion Sciences Announces Expanded Enrollment Criteria for CLEAN-CF Trial
  • Laurent Announces Positive Phase 1b Trial Results for LAU-7b
  • Celtaxsys Announces Positive Phase 1 Clinical Trial Data of CTX-4430
  • Corbus Pharmaceuticals Receives USFDA Clearance to Initiate Phase 2 Study of Resunab(tm)
  • Savara Pharmaceuticals Unveils Positive Phase 2 Trial Results of AeroVanc
  • KaloBios Reports Top-line Data from Phase 2 Study of KB001-A
  • Galapagos NV Nominates GLPG2222 for Combination Therapy with GLPG1837
  • Cystic Fibrosis Trust and NovaBiotics Partner for the Phase IIa Study of Lynovex
  • PTC Therapeutics Initiates Phase 3 Trial of Translarna/ataluren
  • Kamada to Start Clinical Study of Alpha-1 Antitrypsin (AAT) for Cystic Fibrosis

6. PRODUCT LAUNCHES/APPROVALS

  • EC Grants Orphan Drug Designation to Corbus Pharmaceuticals' Resunab
  • FDA Approves Vertex's ORKAMBI(r) for Extended Age Group
  • Pharmaxis Announces Approval of Bronchitol(r) in Russia
  • FDA Grants Orphan Drug Status to Pulmatrix's CF Drug PUR1900
  • ProQR Therapeutics Announces FDA Fast Track Designation for QR-010
  • Alcresta Therapeutics Launches Relizorb Cartridge
  • EC Grants Orphan Medicinal Product Designation to Arch Biopartners' AB569
  • TGV-Inhalonix Receives Orphan Drug Designation for its Mul-1867
  • RespirTech Launches Development of Remote Monitoring System for CF
  • Vertex Pharmaceuticals Receives TGA Approval of ORKAMBI(r)
  • AlgiPharma's OligoG Receives Orphan Drug Designation by FDA
  • Proteostasis Therapeutics Receives FDA Fast Track designation for PTI-428
  • Proteostasis Therapeutics Expands CF Drug Pipeline
  • Vertex Pharmaceuticals Receives Two EU Approvals for KALYDECO(r)
  • USPTO Issues Patent to OrPro Therapeutics' Theradux(tm)
  • FDA Approves Vertex's ORKAMBI
  • Advanced Inhalation Therapies Receives Orphan Medicinal Product Designation for AIT-CF from EMA
  • FDA Approves New Age Group Indication for Vertex Pharmaceuticals' KALYDECO
  • Sandoz Launches Tobramycin Inhalation Solution in the US
  • FDA Approves sNDA for KALYDECO(tm)
  • EC Grants Orphan Designation to Macrolide CF Drug by Synovo GmbH

7. RECENT INDUSTRY ACTIVITY

  • Pharmaxis Enters into Research Collaboration with Woolcock Institute
  • Horizon Pharma Acquires Raptor Pharmaceutical
  • AstraZeneca to Sell Drug Commercialization Rights to Pfizer
  • Vertex Pharmaceuticals and Moderna Therapeutics Enter into Research Collaboration
  • Editas Medicine Enters into Agreement with CFFT for CRISPR/Cas9-based CF Drugs
  • Galapagos and AbbVie Expand Agreement for CF Portfolio
  • Raptor Pharmaceutical Acquires Quinsair from Tripex Pharmaceuticals
  • Galapagos NV Enters into Licensing Agreement with the HUB Foundation
  • Zambon SpA Acquires Nigaard Pharma
  • ManRos and Cyclacel Enter into Licensing Agreement for Seliciclib
  • Vertex and Parion Sciences Collaborate to Develop Investigational CF Treatment
  • Ruthigen and Pulmatrix Enter into Merger Agreement
  • N30 Pharmaceuticals Changes Name to Nivalis Therapeutics
  • Anthera Pharmaceuticals Acquires Sollpura/liprotamase from Eli Lilly
  • OPKO Health Acquires Inspiromatic(tm) dry powder inhaler from Inspiro Medical
  • CURx Pharmaceuticals Enters into Global License Agreement with Gilead Sciences

8. SELECT CLINICAL-STAGE PLAYERS

  • Advanced Inhalation Therapies (AIT) Ltd (Israel)
  • Alaxia SAS (France)
  • AlgiPharma AS (Norway)
  • Anthera Pharmaceuticals, Inc. (USA)
  • Arch BioPartners (Canada)
  • Celtaxsys, Inc. (USA)
  • Concert Pharmaceuticals, Inc. (USA)
  • Corbus Pharmaceuticals Holdings, Inc.(USA)
  • CURx Pharmaceuticals (USA)
  • Nivalis Therapeutics, Inc. (USA)
  • NovaBiotics Ltd (UK)
  • Parion Sciences, Inc. (USA)
  • Pharmaxis Ltd (Australia)
  • PTC Therapeutics, Inc. (USA)
  • Pulmatrix, Inc. (USA)

9. FOCUS ON SELECT GLOBAL PLAYERS

  • AbbVie Inc. (USA)
  • Galapagos NV (Belgium)
  • Genentech, Inc. (USA)
  • Gilead Sciences, Inc. (USA)
  • Novartis AG (Switzerland)
  • Vertex Pharmaceuticals (USA)

10. GLOBAL MARKET PERSPECTIVE

    • Table 4: World Recent Past, Current and Future Analysis for Cystic Fibrosis Therapeutics by Geographic Region - US, Canada, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2022 (includes corresponding Graph/Chart)
    • Table 5: World 7-Year Perspective for Cystic Fibrosis Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Europe, and Rest of World Markets for Years 2016 and 2022 (includes corresponding Graph/Chart)
    • Table 6: World Recent Past, Current and Future Analysis for Cystic Fibrosis Therapeutics by Drug Type - Mucolytics, CFTR Modulators, Anti-Infectives, PERT, and Bronchodilators Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2022 (includes corresponding Graph/Chart)
    • Table 7: World 7-Year Perspective for Cystic Fibrosis Therapeutics by Drug Type - Percentage Breakdown of Dollar Sales for Mucolytics, CFTR Modulators, Anti-Infectives, PERT, and Bronchodilators Markets for Years 2016 and 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Snapshots of Cystic Fibrosis (CF) Prevalence in the US
    • CFFT: NGO Dedicated to Cystic Fibrosis
      • List of Drugs (Companies) in the US Funded by CFFT for Cystic Fibrosis (2016)
    • Drug Pricing in Wake of Orkambi's High Price
    • Clinical Studies
    • Product Launches
    • Strategic Corporate Developments
    • Select Key Players
    • Clinical-Stage Players
  • B. Market Analytics
    • Table 8: US Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2022 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Clinical Studies
    • Product Launch
    • Arch BioPartners: Player Review
  • B. Market Analytics
    • Table 9: Canadian Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2022 (includes corresponding Graph/Chart)

3. EUROPE

  • A. Market Analysis
    • Table 10: Number of Cystic Fibrosis Patients in Europe by Country (2014) (includes corresponding Graph/Chart)
    • Table 11: Proportion of CF Patients in Europe (Adults Vs Children) by Country (2014) (includes corresponding Graph/Chart)
    • Clinical Studies
    • Product Launches
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 12: European Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2022 (includes corresponding Graph/Chart)

4. REST OF WORLD

  • A. Market Analysis
    • Australia - High Out-of-Pocket Expenditure by CF Patients
    • Clinical Studies
    • Product Launch
    • Strategic Corporate Development
    • Select Key Players
  • B. Market Analytics
    • Table 13: Rest of World Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2022 (includes corresponding Graph/Chart)
Back to Top